Hepatosplenic T-Cell Lymphoma · line 1 · ICE (Ifosfamide + Carboplatin + Etoposide), 3 cycles
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 1 |
|---|---|
| Track | aggressive |
| Linked regimen | REG-ICE |
| ID | IND-HSTCL-1L-ICE-ALLOSCT |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | DIS-HSTCL |
| Sources | SRC-NCCN-BCELL-2025 |
Notes
STUB. Дуже rare disease — patient transferred до tertiary center з allo-SCT capability одразу after diagnosis. EBMT Lymphoma Working Party guidelines.
Used By
Algorithms
ALGO-HSTCL-1L- ALGO-HSTCL-1L